Payment overview · 2025
General Payments
$62.33
3 reported records · 2 companies
Healthcare provider profile · identity verified
Meshellia A Hayward, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GREELEYVILLE, SC · NPI 1750349353
Verified facts
What the public records show
CMS Open Payments records show Meshellia A Hayward, FNP received $62.33 in general payments during 2025 across 3 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 69.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.08 | 69.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.25 | 30.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $62.33 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 484 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 472 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 345 | 94 |
| Metformin Hcl | Metformin Hcl | 275 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 63 |
| Losartan Potassium | Losartan Potassium | 214 | 53 |
| Lovastatin | Lovastatin | 206 | 49 |
| Potassium Chloride | Potassium Chloride | 179 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 165 | 38 |
| Fenofibrate | Fenofibrate | 164 | 41 |
| Alendronate Sodium | Alendronate Sodium | 158 | 36 |
| Famotidine | Famotidine | 156 | 52 |
| Metformin Hcl Er | Metformin Hcl | 153 | 47 |
| Gabapentin | Gabapentin | 147 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 44 |
| Omeprazole | Omeprazole | 141 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 35 |
| Ozempic | Semaglutide | 135 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 34 |
| Nifedipine Er | Nifedipine | 127 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 59 |
| Allopurinol | Allopurinol | 122 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 122 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 116 | 35 |
| Ezetimibe | Ezetimibe | 112 | 31 |
| Meclizine Hcl | Meclizine Hcl | 109 | 34 |
| Jardiance | Empagliflozin | 105 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 28 |
| Montelukast Sodium | Montelukast Sodium | 100 | 33 |
| Glimepiride | Glimepiride | 99 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 22 |
| Januvia | Sitagliptin Phosphate | 86 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 25 |
| Farxiga | Dapagliflozin Propanediol | 79 | 18 |
| Lisinopril | Lisinopril | 75 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 19 |
| Valsartan | Valsartan | 67 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 28 |
| Linzess | Linaclotide | 65 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 53 |
| Chlorthalidone | Chlorthalidone | 61 | 16 |
| Carvedilol | Carvedilol | 60 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 19 |
| Benazepril Hcl | Benazepril Hcl | 59 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 17 |
| Glipizide | Glipizide | 56 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 12 |
| Glipizide Er | Glipizide | 50 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 32 |
| Spironolactone | Spironolactone | 39 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 14 |
| Colchicine | Colchicine | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 14 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 22 |
| Fluconazole | Fluconazole | 35 | 26 |
| Furosemide | Furosemide | 35 | 17 |
| Prednisone | Prednisone | 33 | 30 |
| Tramadol Hcl | Tramadol Hcl | 32 | 18 |
| Eliquis | Apixaban | 31 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 26 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 18 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 21 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 20 |
| Baclofen | Baclofen | 21 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 13 |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $62.33 · 3 records | Bayer Healthcare Pharmaceuticals Inc. | FARXIGA, Kerendia | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error